Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer
March 25, 2024 02:00 ET
|
TRiCares SAS
PRESS RELEASE Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer Paris, France and Munich, Germany, March 25, 2024 – TRiCares SAS (“TRiCares”) a...
TRiCares Announces Successful Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Patient with a Pacemaker
December 21, 2023 02:00 ET
|
TRiCares SAS
TRiCares Announces Successful Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Patient with a Pacemaker Paris, France and Munich, Germany, December 21, 2023 –...
TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation
December 06, 2022 02:00 ET
|
TRiCares SAS
TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation Paris, France and Munich,...
TRiCares Raises €47m in a First Closing of its Series C Financing to Fund Further Development of Minimally Invasive Treatment for Tricuspid Regurgitation
September 15, 2022 07:00 ET
|
TRiCares SAS
TRiCares Raises €47m in a First Closing of its Series C Financing to Fund Further Development of Minimally Invasive Treatment for Tricuspid Regurgitation Paris, France and Munich, Germany, September...
TRiCares réalise une Série B de €22 Millions ($25.4 Millions) pour le développement de son traitement mini-invasif de la régurgitation tricuspide
June 04, 2018 02:00 ET
|
TRiCares SAS
TRiCares réalise une Série B de €22 Millions ($25.4 Millions) pour le développement de son traitement mini-invasif de la régurgitation tricuspide Paris (France) et Munich (Allemagne), 4 juin 2018 -...
TRiCares schließt eine Finanzierungsrunde der Serie B in Höhe von € 22 Millionen ($ 25,4 Millionen) zur Investition in die Entwicklung einer minimal invasiven Behandlung von Trikuspidal-Insuffizienz
June 04, 2018 02:00 ET
|
TRiCares SAS
TRiCares schließt eine Finanzierungsrunde der Serie B in Höhe von € 22 Millionen ($ 25,4 Millionen) zur Investition in die Entwicklung einer minimal invasiven Behandlung von Trikuspidal-Insuffizienz ...
TRiCares Closes €22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation
June 04, 2018 02:00 ET
|
TRiCares SAS
TRiCares Closes €22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation Paris, France and Munich, Germany, June 4, 2018 -...